Seroatlas · Human Serome Atlas

PTGDR2

Prostaglandin D2 receptor 2

Also known as: CD294, CRTH2, DP2, GPR44, PD2R2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9Y5Y4
Gene: PTGDR2
Ensembl: ENSG00000183134
Chromosome: 11
Canonical length: 395 aa
Protein class: CD markers, G-protein coupled receptors, Predicted membrane proteins

OverviewNCBI Gene

This gene encodes a G-protein-coupled receptor that is preferentially expressed in CD4+ effector T helper 2 (Th2) cells. This protein is a prostaglandin D2 receptor that mediates the pro-inflammatory chemotaxis of eosinophils, basophils, and Th2 lymphocytes generated during allergic inflammation. Single nucleotide polymorphisms in the 3' UTR of this gene have been associated with asthma susceptibility.[provided by RefSeq, Mar 2011]

Canonical amino-acid sequenceUniProt

395 residues, UniProt reviewed canonical sequence.

>Q9Y5Y4|PTGDR2
     1  MSANATLKPL CPILEQMSRL QSHSNTSIRY IDHAAVLLHG LASLLGLVEN GVILFVVGCR
    61  MRQTVVTTWV LHLALSDLLA SASLPFFTYF LAVGHSWELG TTFCKLHSSI FFLNMFASGF
   121  LLSAISLDRC LQVVRPVWAQ NHRTVAAAHK VCLVLWALAV LNTVPYFVFR DTISRLDGRI
   181  MCYYNVLLLN PGPDRDATCN SRQVALAVSK FLLAFLVPLA IIASSHAAVS LRLQHRGRRR
   241  PGRFVRLVAA VVAAFALCWG PYHVFSLLEA RAHANPGLRP LVWRGLPFVT SLAFFNSVAN
   301  PVLYVLTCPD MLRKLRRSLR TVLESVLVDD SELGGAGSSR RRRTSSTARS ASPLALCSRP
   361  EEPRGPARLL GWLLGSCAAS PQTGPLNRAL SSTSS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PTGDR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 8.8 nTPM

Expression across tissuesHPA

Tissue

stomach: 8.8 nTPM
colon: 8 nTPM
skeletal muscle: 6.8 nTPM
heart muscle: 6.7 nTPM
small intestine: 6.7 nTPM
basal ganglia: 6.1 nTPM

Single-cell type

pericytes: 11 nCPM
hematopoietic stem cells: 6.3 nCPM
cdc: 2.9 nCPM
fibroblasts: 2.9 nCPM
mast cells: 2.9 nCPM
megakaryocyte-erythroid progenitors: 2.6 nCPM

Immune cell

eosinophil: 235 nTPM
basophil: 179 nTPM
non-classical monocyte: 36 nTPM
intermediate monocyte: 11 nTPM
myeloid DC: 5.2 nTPM
total PBMC: 2.3 nTPM

Brain region

amygdala: 4.9 nTPM
cerebral cortex: 4.9 nTPM
thalamus: 4.7 nTPM
basal ganglia: 4.6 nTPM
midbrain: 4.6 nTPM
pons: 4.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.72
gnomAD pLI: 0
gnomAD missense Z: 1.56
DepMap mean gene effect: 0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PTGDR2 as an antibody target. Whether an autoantibody or antibody against PTGDR2 could matter depends on whether native PTGDR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PTGDR2 is annotated at the cell surface, where native PTGDR2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label PTGDR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...